216 related articles for article (PubMed ID: 17378498)
1. Part V. Other beta-lactam antimicrobials.
Gibbs WJ; Cooper TW; Bronze MS; Greenfield RA
J Okla State Med Assoc; 2007 Jan; 100(1):23-5. PubMed ID: 17378498
[No Abstract] [Full Text] [Related]
2. Part II. Introduction to the beta-lactam antibiotics.
Cooper TW; Gibbs WJ; Bronze MS; Greenfield RA
J Okla State Med Assoc; 2006 Oct; 99(10):516-20. PubMed ID: 17125105
[No Abstract] [Full Text] [Related]
3. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
[No Abstract] [Full Text] [Related]
4. Beta-lactam antibiotics: newer formulations and newer agents.
Martin SI; Kaye KM
Infect Dis Clin North Am; 2004 Sep; 18(3):603-19, ix. PubMed ID: 15308278
[TBL] [Abstract][Full Text] [Related]
5. Parenteral carbapenems.
Shah PM
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
[TBL] [Abstract][Full Text] [Related]
6. [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe].
Cavallo JD; Mérens A
Pathol Biol (Paris); 2008; 56(7-8):435-8. PubMed ID: 19019568
[TBL] [Abstract][Full Text] [Related]
7. [Current chemotherapy in urogenital infections. Part 5:Macrolide antibiotics, carbapenems, monobactams, beta-lactamase inhibitors].
Hofstetter A
Fortschr Med; 1992 Jan; 110(1-2):45-6. PubMed ID: 1563698
[No Abstract] [Full Text] [Related]
8. New developments in carbapenems.
Kattan JN; Villegas MV; Quinn JP
Clin Microbiol Infect; 2008 Dec; 14(12):1102-11. PubMed ID: 19076841
[TBL] [Abstract][Full Text] [Related]
9. [Beta-lactam antibiotics].
Suárez C; Gudiol F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):116-29. PubMed ID: 19254642
[TBL] [Abstract][Full Text] [Related]
10. [Ertapenem].
Gobernado M; Acuña C
Rev Esp Quimioter; 2007 Sep; 20(3):277-99. PubMed ID: 18080025
[No Abstract] [Full Text] [Related]
11. Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime.
Bazan JA; Martin SI; Kaye KM
Infect Dis Clin North Am; 2009 Dec; 23(4):983-96, ix. PubMed ID: 19909894
[TBL] [Abstract][Full Text] [Related]
12. The expanding spectrum of beta-lactam antibiotics.
Allan JD; Eliopoulos GM; Moellering RC
Adv Intern Med; 1986; 31():119-46. PubMed ID: 3511613
[No Abstract] [Full Text] [Related]
13. Cephalosporins, carbapenems, and monobactams.
Asbel LE; Levison ME
Infect Dis Clin North Am; 2000 Jun; 14(2):435-47, ix. PubMed ID: 10829264
[TBL] [Abstract][Full Text] [Related]
14. The future of the β-lactams.
Llarrull LI; Testero SA; Fisher JF; Mobashery S
Curr Opin Microbiol; 2010 Oct; 13(5):551-7. PubMed ID: 20888287
[TBL] [Abstract][Full Text] [Related]
15. Re: A VIM-1-metallo-beta-lactamase-producing Klebsiella pneumoniae clinical isolate in an acute hospital in Germany.
Shah PM
Int J Antimicrob Agents; 2009 Oct; 34(4):381. PubMed ID: 19502012
[No Abstract] [Full Text] [Related]
16. New agents in development for the treatment of bacterial infections.
Abbanat D; Morrow B; Bush K
Curr Opin Pharmacol; 2008 Oct; 8(5):582-92. PubMed ID: 18761107
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial therapy: problems and promises, Part I.
Neu HC
Hosp Pract (Off Ed); 1990 May; 25(5):63-74, 77-8. PubMed ID: 2110176
[TBL] [Abstract][Full Text] [Related]
18. Carbapenems in the USA: focus on doripenem.
Lister PD
Expert Rev Anti Infect Ther; 2007 Oct; 5(5):793-809. PubMed ID: 17914914
[TBL] [Abstract][Full Text] [Related]
19. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
20. Surprise neuroprotective potential of beta-lactam antibiotics.
Senior K
Drug Discov Today; 2005 Mar; 10(5):300. PubMed ID: 15749274
[No Abstract] [Full Text] [Related]
[Next] [New Search]
